Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis

References

• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
   PubMed Web of Science ®Google Scholar
• Kerstman E, Ahn S, Battu S, et al. Neuropathic pain. Handb Clin Neurol 2013;110:175-87
   PubMedGoogle Scholar
• Vadalouca A, Raptis E, Moka E, et al. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract 2012;12:219-51
   PubMed Web of Science ®Google Scholar
• Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012;16:191-8
   PubMed Web of Science ®Google Scholar
• Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9
   PubMed Web of Science ®Google Scholar
• Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-82
   PubMed Web of Science ®Google Scholar
• Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag 2012;17:150-8
   PubMed Web of Science ®Google Scholar
• Piano V, Schalkwijk A, Burgers J, et al. Guidelines for neuropathic pain management in patients with cancer: a European survey and comparison. Pain Pract 2013;13:349-57
   Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-5
   PubMed Web of Science ®Google Scholar
• Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. Prim Care Companion CNS Disord 2012;14(3)
   Google Scholar
• Torrance N, Smith BH, Watson MC, Bennett MI. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam Pract 2007;24:481-5
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Mueller-Schwefe G. Opioid-induced constipation – a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications [abstract 656]. Eur J Pain 2006;10(S1):S172
   Google Scholar
• Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
   PubMedGoogle Scholar
• Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-6
   PubMed Web of Science ®Google Scholar
• Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976
   Google Scholar
• Rentz AM, Yu R, Muller-Lissner S, et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83
   PubMedGoogle Scholar
• Rentz AM, van Hanswijck de Jonge P, Leyendecker P, et al. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011;27:35-44
   PubMed Web of Science ®Google Scholar
• Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007;127:199-203
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-57
   PubMed Web of Science ®Google Scholar
• Kosinski M, Janagap CC, Gajria K, et al. Psychometric testing and validation of the Chronic Pain Sleep Inventory. Clin Ther 2007;29(Suppl):2562-77
   PubMedGoogle Scholar
• Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii139-54
   PubMed Web of Science ®Google Scholar
• Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007;64:1475-82
   PubMed Web of Science ®Google Scholar
• Cartoni C, Brunetti GA, Federico V, et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 2012;20:2621-6
   PubMed Web of Science ®Google Scholar
• Gatti A, Sabato AF, Occhioni R, et al. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009;61:129-37
   PubMed Web of Science ®Google Scholar
• Largent-Milnes TM, Guo W, Wang HY, et al. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 2008;9:700-13
   PubMed Web of Science ®Google Scholar
• Ong EC. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes. Oncology 2008;74(Suppl 1):72-5
   PubMedGoogle Scholar
• Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41
   PubMed Web of Science ®Google Scholar
• Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8
   PubMed Web of Science ®Google Scholar
• Weschules DJ, Bain KT, Reifsnyder J, et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med 2006;7:320-9
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Dunlop W, Uhl R, Khan I, et al. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15:564-75
   PubMedGoogle Scholar
• Deshpande MA, Holden RR, Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth Analg 2006;102:1473-9
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Falco FJ, Singh V, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part I: introduction and general considerations. Pain Physician 2013;16(2 Suppl):S1-48
   PubMedGoogle Scholar
• O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112
   PubMed Web of Science ®Google Scholar
• Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
   PubMed Web of Science ®Google Scholar
• Baba M, Gomwo I. [A case of acute exacerbation of neuropathic cancer pain rapidly relieved by simultaneous oral intake of immediate release oxycodone and pregabalin]. Masui 2012;61:1148-52
   PubMedGoogle Scholar
• Gatti A, Longo G, Sabato E, et al. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol 2011;65:317-22
   PubMed Web of Science ®Google Scholar
• Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804-13
   PubMed Web of Science ®Google Scholar
• Shibahara H, Ando A, Suzuki S, et al. [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. Gan To Kagaku Ryoho 2011;38:1675-7
   PubMedGoogle Scholar
• Casty FE, Wieman MS, Shusterman N. Current topics in opioid therapy for pain management: addressing the problem of abuse. Clin Drug Investig 2013;33:459-68
   PubMed Web of Science ®Google Scholar
• Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother 2012;26:348-61
   PubMedGoogle Scholar
• Gudin JA. Clinical strategies for the primary health care professional to minimize prescription opioid abuse. Postgrad Med 2012;124:131-8
   PubMed Web of Science ®Google Scholar
• Katz NP, Birnbaum H, Brennan MJ, et al. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care 2013;19:295-302
   PubMed Web of Science ®Google Scholar
• Ewan EE, Martin TJ. Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain. Anesthesiology 2011;114:624-32
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444-59
   PubMed Web of Science ®Google Scholar
• Cloutier C, Taliano J, O’Mahony W, et al. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 2013;18:75-82
   PubMed Web of Science ®Google Scholar